# Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

> **NCT00855868** · PHASE2 · COMPLETED · sponsor: **Avid Radiopharmaceuticals** · enrollment: 28 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** florbetapir F 18
- **DRUG:** [11C]-PIB

## Key facts

- **NCT ID:** NCT00855868
- **Lead sponsor:** Avid Radiopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-07-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00855868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00855868, "Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00855868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*